SCHEMBL1975692

SCHEMBL1975692

CC(C)(C)OC(=O)NC1(C(=O)NC2CCc3ccccc3-n3ccnc32)CCCC1

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 13/20 0.48
BDKRB1 P46663 3/20 0.41
SCN9A Q15858 2/20 0.40
NPY1R P25929 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976356 0.96 RIPK1 (0.49) RIPK1BDKRB1SCN9ANPY1R
SCHEMBL1976313 0.96 RIPK1 (0.49) RIPK1BDKRB1SCN9ANPY1R
SCHEMBL1977282 0.83 RIPK1 (0.55) RIPK1
SCHEMBL15911360 0.83 RIPK1 (0.55) RIPK1
SCHEMBL15911546 0.80 RIPK1 (0.49) RIPK1
SCHEMBL1979174 0.80 RIPK1 (0.49) RIPK1
SCHEMBL15911572 0.80 RIPK1 (0.49) RIPK1
SCHEMBL1978907 0.79 RIPK1 (0.56) RIPK1
SCHEMBL1979882 0.79 RIPK1 (0.55) RIPK1
SCHEMBL12589927 0.78 RIPK1 (0.51) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509981-B1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE LILLY CO ELI (US) 2014-08-06 EP disclosed
EP-2509981-B1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE LILLY CO ELI (US) 2014-08-06 EP disclosed
US-8299061-B2 Inhibitors of diacylglycerol acyltransferase ELI LILLY AND COMPANY (US) 2012-10-30 US disclosed
US-8299061-B2 Inhibitors of diacylglycerol acyltransferase ELI LILLY AND COMPANY (US) 2012-10-30 US disclosed
EP-2509981-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Eli Lilly and Company (US) 2012-10-17 EP disclosed
WO-2011071840-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE ELI LILLY AND COMPANY (US) 2011-06-16 WO disclosed
US-20110144091-A1 Inhibitors of Diacylglycerol Acyltransferase ELI LILLY AND COMPANY (US) 2011-06-16 US disclosed
US-20110144091-A1 Inhibitors of Diacylglycerol Acyltransferase ELI LILLY AND COMPANY (US) 2011-06-16 US disclosed
WO-2011071840-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE ELI LILLY AND COMPANY (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144091-A1 Inhibitors of Diacylglycerol Acyltransferase DGAT1, DGAT2, LCAT RIPK1 3703/4885BDKRB1 1202/4885SCN9A 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.